NCT00824863 is a Phase 4 clinical trial of ketoconazole 2% foam in Pityrosporum Folliculitis, sponsored by Wayne Fujita, M.D..

Who is sponsoring NCT00824863?

NCT00824863 is sponsored by Wayne Fujita, M.D..

What drugs are being tested in NCT00824863?

Interventions in NCT00824863: ketoconazole 2% foam.

What condition does NCT00824863 study?

NCT00824863 studies Pityrosporum Folliculitis.

Is NCT00824863 still recruiting?

NCT00824863 is currently completed. Last updated 19 August 2014.

Last reviewed 2014-08-19 · How we verify

NCT00824863

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label, Proof of Concept Study to Determine the Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis

Completed Phase 4 Last updated 19 August 2014

What this trial tests

Phase 4 trial testing ketoconazole 2% foam in Pityrosporum Folliculitis in 10 participants. Completed in 1 June 2010.

Timeline

1 December 2008

Primary endpoint
1 May 2010

1 June 2010

Quick facts

Lead sponsor	Wayne Fujita, M.D.
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 December 2008
Primary completion	1 May 2010
Estimated completion	1 June 2010
Sites	1 location across United States

Drugs / interventions tested

ketoconazole 2% foam — full drug profile →

Conditions studied

Pityrosporum Folliculitis — all drugs for Pityrosporum Folliculitis →

Sponsor

Wayne Fujita, M.D. — full company profile →

Who can join

Adults 18 to 65, any sex, with Pityrosporum Folliculitis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Lesion count reduction
Time frame: 90 days

Sponsor's own description

Pityrosporum folliculitis presents as fine superficial follicular pustules and papules on the trunk and upper extremities. Ketoconazole 2% foam was recently approved for the treatment of seborrheic dermatitis in immunocompetent patients 12 years and older. Ketoconazole 2% foam is felt to work by reducing the number of pityrosporum yeast organisms. Safety and efficacy of ketoconazole 2% foam treatment for this fungal infections has not been established. This study is to demonstrate efficacy and safety in the treatment of pityrosporum folliculitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00824863 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wayne Fujita, M.D.
Last refreshed: 19 August 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00824863.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing